Inhibition of neointima formation after experimental coronary artery stenting: A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost

Circulation

Volumn 101, Issue 12, 2000, Pages 1453-1458

  Alt, Eckhard ^a   Haehnel, Iris ^a   Beilharz, Christine ^a   Prietzel, Klaus ^a   Preter, Daniel ^a   Stemberger, Axel ^a   Fliedner, Thilo ^a   Erhardt, Wolf ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angioplasty; Restenosis; Stents

Indexed keywords

HIRUDIN; ILOPROST; MACROGOL; POLYLACTIC ACID; PROSTACYCLIN DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTICLE; BIOCOMPATIBILITY; BLOOD VESSEL INJURY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DELIVERY SYSTEM; HISTOPATHOLOGY; INFLAMMATION; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SHEEP; SUSTAINED DRUG RELEASE; SWINE;

EID: 0034724265     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.12.1453     Document Type: Article

References (36)

1. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Huevel P, Delcan J, Morel MA, for the Benestent Study Group. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Mosis J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
3. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosany M, Baumgartner AR. Inhibitors of angiotensin-converting-enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245: 186-188.
4. Muller DW, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418-432.
5. Hillegras WB, Ohman EM, Califf RM. Restenosis: the clinical issue. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia, Pa: WB Saunders; 1994:415-435.
6. van der Giessen WJ, Lincoff M, Schwartz R, van Beusekom HMM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697.
7. Rübsamen K, Kirchengast M. Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery. Coron Artery Dis. 1998; 1:35-42.
8. Stemberger A, Schmidmaier G, Förster C, Alt E, Kohn J, Calatzis A. New antithrombotic agents: potential for coating biomaterials used in cardiopulmonary bypass. In: Pifarré R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia, Pa: Hanley & Belfus, Inc; 1997:377-386.
9. Herrmann RA, Schmidmaier G, Märkl B, Resch A, Hähnel I, Stemberger A, Alt E. Antithrombotic coating of stents using a biodegradable drug delivery technology. Thromb Haemost. 1999;82:51-57.
10. Murphy JG, Schwartz RS, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Percutaneous polymeric stents in porcine coronary arteries. Circulation. 1992;86:1596-1604.
11. Plenk H Jr. Microscopic evaluation of hard tissue implants. In: Williams DF, ed. Techniques of Biocompatibility Testing. Boca Raton, Fla: CRC Press Inc; 1986;1:42-62.
12. Anderson PG. Restenosis: animal models and morphometric techniques in studies of the vascular response to injury. Cardiovasc Pathol. 1992;1: 263-278.
13. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-274.
14. Agrawal CM, Haas KF, Leopold DA, Clark HG. Evaluation of poly(L-lactic acid) as a material for intravascular polymeric stents. Biomaterials. 1992;13:176-182.
15. Rogers C, Edelman ER. Endovascular stem design dictates experimental restenosis and thrombosis. Circulation. 1995;91:2995-3001.
16. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 1997;29:808-816.
17. De Scheerder IK, Wilczek KL, Verbeken EV, Vandorpe J, Lan PN, Schacht E, De Geest H, Piessens J. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis. 1995;114:105-114.
18. Stein B, Fuster V. Clinical pharmacology of platelet inhibitors. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia. Pa: WB Saunders; 1992:99-119.
19. Wilcox JN. Thrombin and other potential mechanisms underlying restenosis. Circulation. 1991;84:432-435.
20. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1991;84:232-243.
21. Gallo R, Padurean A, Toschi V, Bichler J, Fallon JT, Chesebro JH, Fuster V, Badimon JJ. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation. 1998;97:581-588.
22. Korn RL, Fisher CA, Stenach N, Jeevanandam V, Addonizio VP. Iloprost reduces procoagulant activity in the extracorporeal circuit. J Surg Res. 1993;55:433-440.
23. Shirotani M, Yui Y, Hattori R, Kawai C. U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins. 1991;41:97-110.
24. Knudtson ML, Flintoft VF, Roth DL, Hansen JL, Duff HJ. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1990;15:691-697.
25. Darius H, Nixdorff U, Zander J, Rupprecht HJ, Erbel R, Meyer J. Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty. Agents Actions Suppl. 1992;37:305-311.
26. Banning A, Brewer L, Wendt M, Groves PH, Cheadle H, Penny WJ, Crawtbrd N. Local delivery of platelets with encapsulated iloprost to balloon injured pig carotid arteries: effect on platelet deposition and neointima formation. Thromb Haemost. 1997;77:190-196.
27. Unterberg C, Sandrock D, Nebendahl K, Buchwald AB. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol. 1995;26:1747-1754.
28. Willerson JT, Yao SK, McNatt J, Benedict CR, Anderson HV, Golino P, Murphree SS, Buja LM. Frequency and severity of cyclic flow alterations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci U S A. 1991;88:10624-10628.
29. Sirois MG, Simons M, Kuter DJ, Rosenberg RD, Edelmann ER. Rat arterial wall retains myointimal hyperplastic potential long after arterial injury. Circulation. 1997;96:1291-1298.
30. Gawaz M, Neumann FJ, Ott I, May A, Schömig A. Platelet activation and coronary stent implantation. Circulation. 1996;94:279-285.
31. Hanke H, Kamenz J, Hassenstein S, Oerhoff M, Haase KK, Baumbach A, Betz E, Karsch KR. Prolonged proliferative response of smooth muscle cells after experimental intravascular stenting. Eur Heart J. 1995;16:785-793.
32. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM, EPIC Investigator Group, Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA. 1997;278:479-484.
33. Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ, EPILOG Trial Investigators. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation. 1998;97:857-864.
34. Kastrati A, Schühlen H, Hausleiter J, Walter H, Zitzmann-Roth E, Hadamitzky M, Elezi S, Ulm K, Dirschinger J, Neumann FJ, Schömig A. Restenosis after coronary stent placement and randomization to a four-week combined antiplatelet or anticoagulant therapy: six-month angiographie follow-up of the intracoronary stenting and antithrombotic regimen (ISAR) trial. Circulation. 1997;96:462-467.
35. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans. Circulation. 1998;98: 224-233.
36. Karges HE, Funk KA, Rosenberger H. Activity of coagulation and fibrinolysis parameters in animals. Drug Res. 1994;44:793-797.